Biohaven Pharmaceutical Holding Company Ltd. Stock
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.72 USD | -2.25% | -12.06% | -74.49% |
Apr. 23 | Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO | MT |
Apr. 23 | UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating | MT |
Financials (USD)
Sales 2020 | 63.63 | Sales 2021 | 462.51 | Capitalization | 9.03B |
---|---|---|---|---|---|
Net income 2020 | -767M | Net income 2021 | -847M | EV / Sales 2020 | 87,534,473 x |
Net Debt 2020 | 432M | Net Debt 2021 | 860M | EV / Sales 2021 | 21,377,123 x |
P/E ratio 2020 |
-6.56
x | P/E ratio 2021 |
-10.5
x | Employees | 928 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 90.13% |
1 day | -2.25% | ||
Current month | -74.49% | ||
Current year | -74.49% |
Managers | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Jon Blaskovich
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 17-10-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Gastón Ortega
BRD | Director/Board Member | - | 22-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.97% | 0 M€ | 0.00% | - | |
0.11% | 9 M€ | -.--% | - | |
0.06% | 736 M€ | +6.53% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 38.72 | -2.25% | 971,893 |
24-04-23 | 39.61 | +3.34% | 2,087,194 |
24-04-22 | 38.33 | -1.69% | 1,132,256 |
24-04-19 | 38.99 | -7.52% | 3,353,231 |
24-04-18 | 42.16 | -4.25% | 3,668,414 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-74.49% | 541M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- BHVN Stock